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Additional research on molecular end points
and other biological approaches has been
recommended for evaluating the toxicity of
chemicals (Committee on Toxicity Testing
and Assessment of Environmental Agents
2007). However, currently and for the fore-
seeable future, short- and long-term bioassays
represent the most reliable way to evaluate
and profile the toxicology of chemicals to
which humans are exposed, especially for pre-
dicting and preventing long-term adverse
exposure effects, including cancer. We focus
here on two potentially important means of
increasing the sensitivity of carcinogenesis
bioassays for identifying potentially carcino-
genic food additives, pesticides, workplace
chemicals and contaminants, pharmaceuti-
cals, industrial chemicals, consumer products,
and other natural and synthetic chemicals.
Chemical carcinogenesis bioassays in ani-
mals have long been recognized and accepted
as valid predictors of potential cancer hazards
to humans (Huff 1999, 2002; Rall 2000;
Tomatis 2006; Tomatis and Huff 2002). The
relevance of experimental bioassays to humans
rests on four well-accepted observations:
a) Experimental animals and humans are mam-
mals sharing many basic genetic, pharmaco-
logic, toxicologic, and carcinogenic responses;
b) findings from independently conducted
bioassays on the same chemicals are consistent;
c) all known human carcinogens that have
been tested adequately are also carcinogenic in
animals and, almost without exception, share
identical target sites; and d) nearly one-third of
human carcinogens were first discovered to
induce cancer in animals (e.g., 1,3-butadiene,
diethylstilbestrol, dioxins, ethylene oxide,
2-naphthylamine, formaldehyde, vinyl chlo-
ride), although most of these were not regu-
lated until human evidence mounted. Thus, in
light of the fact that animal bioassays predict
human cancer risks, conducting more sensitive
tests would better protect the public, and espe-
cially workers, from involuntary exposure to
animal carcinogens.
Equivocal Carcinogenesis
Bioassay Results
Worldwide, most carcinogenesis bioassays
expose rodents for ≤ 2 years, starting after
birth and ending well before natural death,
which typically occurs for rats at 3 years and
for mice at 2.5 years. In fact, as examples out-
lined below indicate, timing and duration of
exposure and observation in chemical carcino-
genesis bioassays may determine whether the
results are positive or negative.
Aspartame. Two 3-year-long lifetime
feeding studies using Sprague-Dawley rats,
conducted by the European Ramazzini
Foundation of Oncology and Environmental
Sciences in Bologna, Italy, have raised ques-
tions about the safety of the artificial sweet-
ener aspartame (Abdo et al. 2007; Belpoggi
et al. 2006; Huff and LaDou 2007; Soffritti
et al. 2006, 2007). The first study began
exposures at 8 weeks of age (postnatal study),
whereas the second began exposures in utero.
Exposures in both studies continued until the
animals’ natural deaths, with the oldest rats
living about 2.75–3.0 years. In the postnatal
lifetime exposure study, aspartame caused
mainly leukemias and lymphomas in males
and females, peripheral nerve schwannomas
in males, and possibly increases in total
malignant tumors, kidney tumors, and brain
tumors (Soffritti et al. 2006). The prenatal
lifetime study showed increased incidences of
lymphomas/leukemias in males and females,
mammary gland cancers in females, and total
tumor-bearing males (Soffritti et al. 2007).
[The European Food Safety Authority and
the U.S. Food and Drug Administration
(FDA) dispute the conclusion of the first
study and have not yet reviewed the second.]
Previous 2-year feeding studies in Wistar rats
did not detect increased tumor incidences
(Ishii et al. 1981), although there was some
debate about the occurrence of rare tumors of
the brain, also observed in the Ramazzini
studies, and there are general concerns regard-
ing the questionable quality of other earlier
negative studies (Davis 2007).
Cadmium. Cadmium is another telling
example of a chemical that was not shown to
be carcinogenic in 2-year studies of Wistar
rats (Löser 1980), but caused various tumors
in the lung in a 31-month study of Wistar
rats (Takenaka et al. 1983). According to
Takenaka et al. (1983), “length of experimen-
tal duration was the likely reason” their study,
but not the other study, showed positive
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BACKGROUND: Chemical carcinogenesis bioassays in animals have long been recognized and
accepted as valid predictors of potential cancer hazards to humans. Most rodent bioassays begin
several weeks after birth and expose animals to chemicals or other substances, including workplace
and environmental pollutants, for 2 years. New ﬁndings indicate the need to extend the timing and
duration of exposures used in the rodent bioassay.
OBJECTIVES: In this Commentary, we propose that the sensitivity of chemical carcinogenesis bio-
assays would be enhanced by exposing rodents beginning in utero and continuing for 30 months
(130 weeks) or until their natural deaths at up to about 3 years.
DISCUSSION: Studies of three chemicals of different structures and uses—aspartame, cadmium, and
toluene—suggest that exposing experimental animals in utero and continuing exposure for
30 months or until their natural deaths increase the sensitivity of bioassays, avoid false-negative
results, and strengthen the value and validity of results for regulatory agencies.
CONCLUSIONS: Government agencies, drug companies, and the chemical industry should conduct
and compare the results of 2-year bioassays of known carcinogens or chemicals for which there is
equivocal evidence of carcinogenicity with longer-term studies, with and without in utero exposure.
If studies longer than 2 years and/or with in utero exposure are found to better identify potential
human carcinogens, then regulatory agencies should promptly revise their testing guidelines, which
were established in the 1960s and early 1970s. Changing the timing and dosing of the animal
bioassay would enhance protection of workers and consumers who are exposed to potentially dan-
gerous workplace or home contaminants, pollutants, drugs, food additives, and other chemicals
throughout their lives.
KEY WORDS: animal cancer tests, aspartame, bioassay designs, bisphenol A, cadmium, carcinogenicity,
chemical carcinogens, genistein, toluene, toxicology. Environ Health Perspect 116:1439–1442
(2008). doi:10.1289/ehp.10716 available via http://dx.doi.org/ [Online 30 June 2008]carcinogenicity results. Interestingly, Löser
(1980) exposed animals to cadmium for
24 months, about 6 months longer than did
Takenaka et al. (1983), who exposed animals
for 18 months but observed them 13 months
longer than did Löser. 
Toluene. Soffritti et al. (2004) orally
treated Sprague-Dawley rats with toluene for
2 years and observed them for an additional
6 months. At the end of this observation
period, signiﬁcant increases occurred in several
tumors, including total malignant tumors
(Figure 1); tumors of subcutaneous tissue,
mammary glands, and oral cavity, lips, and
tongue; and lymphomas/leukemias. In con-
trast, the National Toxicology Program’s
(NTP) 2-year inhalation bioassays in Fischer
rats and B6C3F1 mice did not detect any
chemically related tumors (Huff 2003). Thus,
the 26 extra weeks of observation without
additional exposure in the Sprague-Dawley
study (Soffritti et al. 2004) allowed time for
tumors to develop, progress, and become
detectable. An animal strain–response differ-
ence between laboratories is possible, but this
was not the case in all other comparisons of
carcinogenicity studies performed by the
Ramazzini Foundation and the NTP, nor
have such differences been shown generically
(Huff 2002).
Discussion
Advantages of beginning exposure during
intrauterine development. Over the years, the
NTP has tested chemicals for possible car-
cinogenicity in about 600 2-year bioassays,
most often using both sexes of two strains of
rodents, rats and mice. Yet only 7 (~ 1%) of
those involved in utero/perinatal exposures:
• Azidothymidine transplacental carcinogenesis
study (NTP 2006)
• t-Butylhydroquinone (TBHQ) (NTP 1997a)
• D&C yellow no. 11 (NTP 1997b)
• 5,5-Diphenylhydantoin (phenytoin) (NTP
1993a)
• Ethylene thiourea (NTP 1992)
• Genistein (NTP 2007)
• Polybrominated biphenyl mixture (Firemaster
FF-1) (NTP 1993b).
The developing fetus is particularly sensi-
tive to effects of hormones and estrogenic (and
other) chemicals. For instance, prenatal expo-
sure of humans to diethylstilbestrol (DES)
provides a classic example of transplacental
carcinogenesis predicted in animals (Newbold
and McLachlan 1982) and confirmed in
humans (Herbst et al. 1971; Palmlund 1996;
Palmer et al. 2006). Because exposures to
phytoestrogens and synthetic hormonally
active compounds, such as bisphenol A
(BPA), are increasing in diets of infants and
children, these materials need to be investi-
gated in prenatal and perinatal bioassays.
Newbold et al. (2001) evaluated the endocrine
disruptor genistein in a 5-day neonatal expo-
sure in CD-1 mice and after 18 months found
increases in adenocarcinomas of the uterus.
They then designed expanded bioassay with
three exposure regimens: a) continuous expo-
sure from conception through 2 years of age;
b) exposure from conception through
20 weeks (140 days) followed by a control diet
to 2 years of age; and c) dosing from concep-
tion through weaning (21 days) followed by
the control diet to 2 years. Increases in tumors
(mammary gland and pituitary gland tumors)
were observed only in the ﬁrst experiment. 
An in utero exposure protocol used to
study effects of TBHQ (Abdo and Kari 1996;
NTP 1997a) 2.5 years after exposure began
should be considered by the NTP and regula-
tory agencies as a model for cancer bioassays.
Female F0 rats were fed diets containing vary-
ing amounts of TBHQ, beginning 2 weeks
before cohabitation with males and continu-
ing through gestation and lactation until F1
pups were weaned. F1 rats continued to
receive postweaning diets containing TBHQ
for 123 weeks for males and 129 weeks for
females. Interestingly, despite this inclusive
exposure protocol from conception up to
nearly 30 months of age, there was no evi-
dence of carcinogenicity. In fact, decreases in
mammary gland tumors occurred in both
sexes. These ﬁndings certainly contradict the
notion that studies using in utero exposure
with follow-up for about 2.5 years invariably
result in carcinogenic activity.
In contrast, recent studies of the widely
used plasticizer additive BPA indicate that pre-
natal exposures can induce obesity in offspring
(Dolinoy et al. 2007), a phenomenon that has
not been observed with postnatal exposures
alone. Prenatal exposure of pregnant Agouti
Avy mice to BPA, which is a major component
of polycarbonate plastics and epoxy resins, sig-
niﬁcantly reduced DNA methylation (Dolinoy
et al. 2007). Others have reported that prenatal
BPA also increases mammary tumor develop-
ment and other developmental abnormalities
(Soto et al. 2008), and may increase recurrent
miscarriages (Sugiura-Ogasawara et al. 2005).
Thus, experiments of prenatal exposure to BPA
find that such exposures imprint mammary
cells, leaving them especially sensitized to later
cell growth and hormonal stimulation—
characteristics also found in tumors. It may
also be relevant that low levels of BPA have
been found to activate genes in noncancerous
breast cells in a way that mimics that seen in
highly aggressive breast cancer (Dairkee et al.
2008), indicating that BPA plays a critical role
both prenatally and postnatally.
Advantages of studies with longer observa-
tion periods versus 2-year studies. Experimental
studies should be designed with optimum sensi-
tivity to identify likely adverse health problems
throughout humans’ increasing life span.
Humans, of course, consume or are exposed to
countless natural and synthetic substances dur-
ing gestation, nursing, and the rest of their lives.
In modern societies, proportionally more peo-
ple are living until their 70s, 80s, and 90s, long
after prenatal and childhood exposures and
retirement from workplace exposures. Because
most long-term rodent carcinogenesis studies
do not involve in utero exposure and are inten-
tionally terminated after 2 years (104 weeks) of
exposure, they cannot shed light on the effects
of chemicals on embryos/fetuses/neonates or
“elderly” animals. Likewise, studies truncated
after 2 years of exposure do not allow sufﬁcient
latency periods for late-developing tumors, such
as the 80% of all human cancers that occur
after 60 years of age. Because a 2-year-old rat is
roughly equivalent to a 60- to 65-year-old per-
son, conventional 2-year-long bioassays cannot
detect tumors that will develop later in life.
Although some researchers have suggested
reducing the duration of rodent studies to
18 months (e.g., Davies et al. 2000), scientists
at the National Institute of Environmental
Health Sciences reject that recommendation,
noting that animals in such studies would be
the equivalent of humans only 30–50 years of
age and would reduce statistical power
(Bucher 2002; Haseman et al. 2001; Kodell
et al. 2000). Instead, a number of researchers
Huff et al.
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Figure 1. Cumulative prevalence of total malignant tumors in females and males histopathologically
observed, by age at death, among Sprague-Dawley rats treated with 500 mg/kg body weight/day of
toluene for 104 weeks and then kept under control conditions until death or 130 weeks (experiment BT
903). Dashed lines indicate 112 weeks, the typical termination of NTP studies. Arrows indicate beginning of
exposure. Reproduced from Soffritti et al. (2004) with permission from the European Ramazzini Foundation. 
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have recommended extending the duration of
rodent studies to ≥ 30 months (Davis 2007;
Haseman et al. 2001; Huff 2002; Huff et al.
2007; Maltoni 1995; Soffritti et al. 2002). In
some cases, as the Ramazzini Foundation some-
times does, exposure to industrial chemicals is
stopped after 2 years (“retirement age”), and the
animals are then observed until ≥ 30 months of
age to determine delayed or persistent carcino-
genic activity (Maltoni 1995; Soffritti et al.
2002). Ceasing exposure at 2 years without
monitoring tumor development for additional
time cannot estimate the impact of food addi-
tives, drugs, and other chemicals on humans
who die in their 70s or later. 
Advantages of 2-year studies over studies
with longer observation periods. Two-year
studies do have certain advantages over longer
studies. First, because these studies are stan-
dard protocols and designs, a great deal of
experience has been gained from them,
including information on tumor formation in
historical controls. 
Second, these briefer studies yield some-
what quicker results, which is useful for pro-
tecting public health. 
Third, shorter tests are somewhat, but not
proportionately, cheaper to conduct. However,
because of the numerous ﬁxed costs of animal
studies (animals, postmortem pathology, etc.),
longer studies are not commensurately margin-
ally costlier. In any case, economy should not
trump sensitivity and the reliability of results.
Ancillary costs of longer studies include
educating researchers on how to conduct them
and carrying out more frequent inspections at
the later stages for moribund or sickly animals
to minimize autolysis in animals that die natu-
rally at night and may not be discovered
immediately. However, certain tissues are
affected more than others, and tumors would
remain relatively inviolate; moreover, even in
2-year studies, only 60–70% of animals
remain alive at the end. 
Fourth, some tumor rates increase, and
old-age lesions may complicate discerning
nonneoplastic effects. 
Finally, whereas tumor incidences in vari-
ous strains of control animals are known on
the basis of numerous studies, it would take
time to develop a body of data on tumor inci-
dence and other abnormalities for these
longer time periods.
Some researchers have argued that higher
rates of spontaneous tumors and other factors
would undermine the value of longer-term
studies (Solleveld and McConnell 1985), but
those assertions are not based on actual bio-
assays—comparing, for instance, the relative
abilities of 24-month, 30-month, and life-
time bioassays to detect the effects of known
carcinogens. Most important, any “savings”
accruing from current testing protocols are
only illusory if false-negative results lead to
the exposure of millions of people to sub-
stances that caused cancer or other maladies.
To maximize the knowledge gained from
costly full-lifetime studies, protocols should be
expanded to provide for periodic sacriﬁcing to
determine time-to-tumor and biological sam-
pling to determine internal doses, metabolite
levels, genetic alterations, and other data rele-
vant to characterizing the pharmacokinetic
and pharmacodynamic activity of toxicity and
noncancer disease.
Conclusion
The evidence presented here indicates that
extending animal bioassays beyond 2 years
and beginning exposure in utero, especially for
endocrine-disrupting chemicals that “act”
preferentially in early life (Huff 1996, 2001;
Huff et al. 1996; Newbold et al. 2001;
Newbold and McLachlan 1982; Thayer and
Foster 2007; Tomatis et al. 1992; Yamasaki
et al. 1992), would provide more reliable
and appropriate indicators of human risk.
The FDA, U.S. Environmental Protection
Agency, Occupational Safety and Health
Administration, Consumer Product Safety
Commission, NTP, and others should recon-
sider their designs of “best practices” regarding
long-term studies of chemicals for detection of
carcinogenic risks to humans. We urge those
governmental agencies, perhaps in conjunction
with such other agencies as the World Health
Organization’s International Agency for
Research on Cancer, to conduct and compare
the results of 2-year and longer-term feeding
studies, with and without in utero exposure, of
known or equivocal-evidence carcinogens.
It is noteworthy that the FDA already
“recommends that in utero exposure be
included in carcinogenicity studies due to the
fact that exposure to food ingredients occurs
during all stages of life” (FDA 2006). If bio-
assays demonstrate that studies longer than
2 years and/or with in utero exposure are better
able to identify carcinogens, regulatory agen-
cies should revise their testing guidelines, most
of which were established > 40 years ago
(Bucher 2002; Huff and Moore 1984;
Weisburger 1983).
Another gap in regulatory protocols
involves male-mediated teratogenesis—the
study of compounds’ capacity to impede repro-
ductive health of offspring through paternal
genomic and other male-mediated routes
(Davis et al. 1992). Regarding endocrine
disruptors and other chemicals that cross the
placenta and affect critical windows of develop-
ment, one need not wait for comparison bio-
assays before routinely conducting in utero and
longer-term bioassays. 
Beneﬁts to public health from conducting
more sensitive bioassays that reﬂect early life
exposures and continue throughout a natural
lifetime of observation could be considerable.
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